Beximco Pharmaceuticals has reported a profit of Tk 694 crore for the financial year ended June, alongside a dividend payout decision worth Tk 212 crore, even as the company continues to navigate governance disputes and international trading uncertainty.
The results were finalised at a board meeting held on Tuesday, following approval from the Bangladesh Securities and Exchange Commission. The meeting confirmed the audited financial statements for the 2024–25 financial year, which also included quarterly accounts up to March. Despite recent disruptions in corporate governance and regulatory scrutiny, the company has maintained a substantial profit level.
For the year under review, the board declared a cash dividend of 47.5 per cent, equivalent to Tk 4.75 per share. Based on this payout structure, total dividend distribution will amount to Tk 212 crore. The record date has been set for 2 August, meaning shareholders holding shares on that date will be eligible to receive the declared dividend. Final approval of the dividend will follow the annual general meeting, which will be scheduled after court clearance.
The distribution of dividends reflects the company’s ownership structure. Sponsor-directors, who hold just over 30 per cent of shares, are expected to receive around Tk 64 crore. Foreign investors, with more than 27 per cent shareholding, will receive approximately Tk 58 crore. Institutional investors, holding roughly a quarter of the company, are set to receive about Tk 54 crore. Retail investors, who collectively own around 17 per cent, will receive nearly Tk 36 crore.
The company’s ownership is linked to businessman Salman F Rahman and his family, who served as close associates of former Prime Minister Sheikh Hasina before the political transition in 2024. Following the change in government, Salman F Rahman was arrested and remains in custody. Subsequently, the regulator appointed nine independent directors to the board in early 2025, a move that triggered legal challenges from the company and contributed to a prolonged suspension of board meetings for nearly 18 months.
The governance dispute also affected the company’s international listing. London Stock Exchange suspended trading of Beximco Pharma shares on its Alternative Investment Market (AIM) on 2 January after the company failed to publish required financial reports within regulatory deadlines. Continued suspension raised the risk of delisting under AIM rules, which allow removal if trading remains halted for six months.
Pressure from international institutional investors eventually prompted regulatory intervention, leading to renewed board activity and the publication of delayed financial statements. Following the announcement of results and dividend news, the company’s shares still fell on the Dhaka Stock Exchange on Wednesday, dropping by Tk 3.60, or around 2.5 per cent, to Tk 142. However, trading activity remained strong, with shares worth Tk 44 crore changing hands by early afternoon, making the company one of the most actively traded stocks of the day.
Comments